IRIDEX (NASDAQ:IRIX) Posts Earnings Results, Misses Estimates By $0.04 EPS

IRIDEX (NASDAQ:IRIX – Get Free Report) posted its quarterly earnings results on Tuesday. The medical equipment provider reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.04), FiscalAI reports. The firm had revenue of $10.16 million for the quarter, compared to analysts’ expectations of $12.64 million.

IRIDEX Trading Up 1.7%

Shares of IRIX traded up $0.01 during midday trading on Tuesday, reaching $0.70. 143,120 shares of the stock were exchanged, compared to its average volume of 215,764. The company has a market capitalization of $12.29 million, a P/E ratio of -3.50 and a beta of 0.64. IRIDEX has a 52 week low of $0.61 and a 52 week high of $1.65. The company’s 50 day moving average is $0.71 and its two-hundred day moving average is $1.00.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 3rd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, IRIDEX has a consensus rating of “Hold” and a consensus target price of $3.00.

Check Out Our Latest Research Report on IRIX

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation develops, manufactures and markets laser-based medical systems and related delivery devices for eye-care professionals. Its products are used to treat retinal diseases and glaucoma, including through laser procedures designed to preserve or improve vision. The company’s offerings include ophthalmic laser systems such as the Cyclo G6 glaucoma laser system and IQ-series photocoagulators, along with treatment-delivery devices and technologies including MicroPulse laser therapy. IRIDEX was founded in 1989 and serves customers internationally through direct sales and distribution partners.

Read More

Earnings History for IRIDEX (NASDAQ:IRIX)

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.